

CITATION REPORT

List of articles citing

Infliximab pharmacokinetics in inflammatory bowel disease patients

DOI: 10.1097/ftd.ob013e318180e300

Therapeutic Drug Monitoring, 2008, 30, 523-9.

Source: <https://exaly.com/paper-pdf/44938156/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
159	Pathogenesis of osteoporosis: concepts, conflicts, and prospects. 2005 , 115, 3318-25		1089
158	Infliximab: A Review of its Use in the Treatment of Crohn's Disease. 2009 , 1, CMT.S2250		
157	[Pharmacokinetics (PK) of mAbs]. 2009 , 25, 1057-62		9
156	Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. 2009 , 18, 47-73		36
155	Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. 2009 , 61, 569-76		30
154	Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009 , 36, 407-20	2.7	30
153	Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. 2009 , 65, 1211-28		229
152	Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. 2009 , 11, R178		50
151	Current world literature. 2009 , 25, 579-95		
150	Bibliography. Current world literature. Paediatric and neonatal infections. 2009 , 22, 326-30		
149	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. 2010 , 25, 886-91		17
148	Population pharmacokinetics of therapeutic monoclonal antibodies. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 633-59	6.2	332
147	Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. 2011 , 46, 310-8		151
146	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. 2011 , 13, R105		109
145	Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti-TNF Biopharmaceuticals and Anti-Drug Antibodies. 2011 , 81-101		2
144	Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 7-19	3.8	22
143	The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 243-50	6.1	51

142	High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1053-8	6.1	139
141	Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. 2011 , 33, 946-64		198
140	Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011 , 38, 803-32	2.7	11
139	Severe neutropenia following infliximab treatment in a child with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, E17-8	4.5	6
138	Interindividual variability of response to rituximab: from biological origins to individualized therapies. 2011 , 17, 19-30		69
137	Anti-TNF- β therapies: perspectives for evidence-based personalized medicine. 2012 , 4, 1167-79		52
136	Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. 2012 , 47, 662-8		63
135	Glycoengineering of protein-based therapeutics. 2012 , 94-123		2
134	Optimizing immunomodulators and anti-TNF agents in the therapy of Crohn disease. 2012 , 41, 393-409, ix		7
133	Doit-on mesurer les concentrations sériques d'anti-TNF- β et/ou d'anticorps anti-médicament au cours de la polyarthrite rhumatoïde?. 2012 , 79, 97-100		
132	Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. 2012 , 91, 635-46		349
131	Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 108-11	1.5	47
130	Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 358-61	1.5	22
129	Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. 2012 , 10, 1079-87; quiz e85-6		167
128	Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. 2012 , 8, 141-60		92
127	Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2209-17	4.5	75
126	Durability of infliximab dose intensification in Crohn's disease. 2012 , 57, 1013-9		18
125	Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 55-65	3.8	40

124	Should anti-TNF- α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?. 2012 , 79, 109-12		24
123	Therapeutic drug monitoring of biologics for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 349-58	4.5	96
122	Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 1172-83	6.1	39
121	Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. <i>AAPS Journal</i> , 2013 , 15, 30-40	3.7	32
120	The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. <i>AAPS Journal</i> , 2013 , 15, 172-82	3.7	26
119	Serum infliximab concentrations in pediatric inflammatory bowel disease. 2013 , 48, 35-41		35
118	Surgery for Crohn's disease and anti-TNF agents: the changing scenario. 2013 , 7, 689-700		9
117	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 853-67	1.5	142
116	Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. 2013 , 108, 1426-38		88
115	Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease. 2013 , 47, 491-5		36
114	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. 2013 , 54, 53-7		36
113	Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 530-8	3.2	87
112	Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. 2013 , 5, 614-9		36
111	Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. 2013 , 25, 714-8		10
110	Therapeutic drug monitoring in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3475-84	5.6	46
109	Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. 2014 , 4,		7
108	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 118-28	3.8	57
107	Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 2247-59	4.5	178

106	Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. 2014 , 20, 81-101		13
105	Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1177-86	4.5	67
104	Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. 2014 , 43, 78-84		75
103	Targeting TNF- α for the treatment of inflammatory bowel disease. 2014 , 14, 75-101		94
102	Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. 2014 , 29, 1177-85		25
101	Pharmacokinetics of biologics and the role of therapeutic monitoring. 2014 , 43, 565-79		6
100	The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review. 2014 , 18, 1216-24		26
99	Biologic therapies in inflammatory bowel disease. 2014 , 163, 533-56		36
98	Antidrug Antibodies: B Cell Immunity Against Therapy. 2015 , 82, 184-90		6
97	Risk of Post-Operative Infections with Anti-TNF Therapy. 152-158		
96	A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade $\text{\textcircled{R}}$) in Healthy Subjects. <i>BioDrugs</i> , 2015 , 29, 381-8	7.9	42
95	Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 529-39	6.1	43
94	An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2172-7	4.5	32
93	Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1709-18	4.5	43
92	Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1683-94	4.5	47
91	Emerging Mechanisms of Action and Loss of Response to Infliximab in Ibd: A Broader Picture. 2015 , 05,		2
90	Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?. 2015 , 136, 814-6		16
89	Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 551-62	6.2	43

88	Pharmacokinetics of adalimumab in Crohn's disease. 2015 , 71, 1155-7		24
87	Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S39-50	2.9	61
86	Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 783-92	4.5	63
85	The impact of preoperative serum anti-TNF therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. 2015 , 261, 487-96		119
84	Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 182-97	4.5	115
83	A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease. 2015 , 71, 1541-2		12
82	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1999-2015	4.5	71
81	Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1655-61	4.5	9
80	Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. 2016 , 9, 513-26		46
79	The underlying inflammatory chronic disease influences infliximab pharmacokinetics. 2016 , 8, 1407-1416		37
78	Biologic Therapeutic Drug Monitoring in Australia. 2016 , 31 Suppl 1, 8-9		
77	Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 969-75	4.5	39
76	Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. 2016 , 15, 43-52		58
75	A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 773-8	1.5	43
74	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 617-630	6.1	50
73	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1773-1781	3.8	23
72	Theranostic of biopharmaceuticals. 2017 , 175, 67-74		5
71	A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1287-1301	6.2	92

70	One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFα Trough and Antibody Levels Assessed. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1154-1159	4.5	9
69	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 322-326	3.2	18
68	Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. 2017 , 34, 1556-1563		10
67	Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. 2017 , 16, 303-317		17
66	Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 2172-2179	4.5	14
65	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1037-1053	6.1	165
64	Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study. 2017 , 95, 67-71		11
63	The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. 2017 , 46, 661-677		7
62	Outcome after restorative proctocolectomy and ileal pouch-anal anastomosis in children and adults. 2017 , 104, 1640-1647		15
61	Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 272-282	4.5	18
60	Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 75-81	4.5	10
59	Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. <i>AAPS Journal</i> , 2017 , 19, 223-233	3.7	15
58	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 246-255	1.5	13
57	Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study. <i>Intestinal Research</i> , 2017 , 15, 487-494	4.1	6
56	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1075-1106	6.2	10
55	Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 929-942	6.2	52
54	Postoperative Morbidity Risks Following Ileocolic Resection for Crohn's Disease Treated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 422-432	4.5	19
53	Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018 , 66, 268-273	2.8	15

52	Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1173-1184	6.2	10
51	Mechanism of Action and Pharmacokinetics of Biologics. 2018 , 1-11		2
50	Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1900-1907	4	4
49	Quantitation of Infliximab and Detection of Antidrug Antibodies in Serum by Use of Surface Plasmon Resonance. <i>Journal of Applied Laboratory Medicine</i> , 2018 , 2, 725-736	2	3
48	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 169-187	6.2	20
47	Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 172-179	4.5	19
46	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 15-37	6.2	46
45	Earlier discontinuation of TNF- α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 386-396	6.1	12
44	Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. <i>BioDrugs</i> , 2019 , 33, 453-468	7.9	7
43	Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 835-844	4.5	19
42	Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019 , 46, 543-551	2.7	3
41	Endo-sponge Assisted Early Surgical Closure of Ileal Pouch-anal Anastomotic Leakage Preserves Long-term Function: A Cohort Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1537-1545	1.5	15
40	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. <i>Antibodies</i> , 2019 , 8,	7	22
39	Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 125-131	4.5	7
38	Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 37-49	6.2	13
37	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1443-1451	4.5	6
36	The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2020 , 44-45, 101670	2.5	0
35	Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 857-874	6.2	16

34	Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 1489-1500	3	3
33	Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 612-628	6.1	22
32	Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 54-72	6.1	59
31	Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2374-2384	3.8	0
30	Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1594-1595	3.8	0
29	The Impact of Rectal Stump Inflammation After Subtotal Colectomy on Pouch Outcomes in Ulcerative Colitis Patients. <i>Journal of Crohns and Colitis</i> , 2020 ,	1.5	1
28	Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. <i>Frontiers in Pharmacology</i> , 2020 , 11, 610806	5.6	6
27	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
26	Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Study.		0
25	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. <i>BMJ Open</i> , 2021 , 11, e043921	3	2
24	External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. <i>Pharmaceutics</i> , 2021 , 13,	6.4	0
23	Infliximab Treatment Does Not Lead to Full TNF- α Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
22	External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
21	The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2021 , 36, 1231-1241	3	3
20	Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 224-233	2.9	4
19	Personalized Medicine: Integrating Individual Exposure and Response Information at the Bedside. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 65-82	0.5	2
18	Anti-TNF and Pouch Surgery for Ulcerative Colitis: The Ones who Blame for More Complications?. <i>Current Drug Targets</i> , 2019 , 20, 1349-1355	3	2
17	Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients. <i>Open Rheumatology Journal</i> , 2017 , 11, 75-87	0.2	12

16	Immunogenicity of Anti-TNF- β Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence. <i>Frontiers in Immunology</i> , 2015 , 6, 152	8.4	23
15	Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 197-204	5.6	30
14	Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017 , 23, 414-425	5.6	14
13	Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn's disease. <i>World Journal of Gastroenterology</i> , 2018 , 24, 2036-2046	5.6	5
12	Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017 , 8, 155-161	3	13
11	Does infliximab increase complications after surgery for inflammatory bowel disease?. <i>F1000 Medicine Reports</i> , 2009 , 1,		9
10	Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2016 , 5,	0.2	
9	Infliximab Efficacy May Be Linked to Full TNF- β Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. <i>Pharmaceutics</i> , 2021 , 13,	6.4	
8	Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 131-4	0.7	3
7	Benign Gastrointestinal Conditions. 2022 , 297-330		
6	Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. <i>CPT: Pharmacometrics and Systems Pharmacology</i> ,	4.5	0
5	Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars. Volume 16, 2803-2815		1
4	Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort. 2022 , 12, e061474		1
3	Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. 2022 , 14, 2095		0
2	A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.		1
1	Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade β in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis.		0